FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Angioedema Treatment Market Overview:

According to FutureWise analysis the market for angioedema treatment is expected to register a CAGR of 16.80% from 2023-2031.

Angioedema is subcutaneous tissues or submucosal tissues circumscribed non-pitting edema affecting lips, face, neck, and extremities oral cavity, larynx, and gut. It becomes life-threatening when it involves the larynx, while intestinal angioedema is painful and mimics the acute abdomen. In some cases, internal organs like the esophagus, stomach, or bowel may also swell, leading to discomfort in the chest or abdomen. Angioedema may cause itching, tingling, or burning sensations, but sometimes there are no other symptoms except for the discomfort of the swelling itself. Sometimes, the swelling can be painful, especially when it happens around joints. These swellings can be big and might last for several days. If the swelling is always present and doesn't go away, other potential causes should be investigated.

The treatment of angioedema varies based on its cause, but the top priority is maintaining an open airway to ensure proper breathing. In emergencies, a breathing tube may be inserted for safety. Allergic reactions can be managed with epinephrine, found in an EpiPen. Additionally, antihistamines and corticosteroids are other medications that can be used to address angioedema.

FutureWise Market Research has published a report that provides an insightful analysis angioedema treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, angioedema treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Angioedema Treatment Market:

Shire plc.
CSL Limited
Pharming Group NV
Ionis Pharmaceuticals, Inc.
iBio Inc.
BioCryst Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Ambulatory Aids Market:

In June 2022- BioCryst Pharmaceuticlas, Inc., a company that designs and develops small molecules medicine for rare diseases like hereditary angioedema(HAE) and fibrodysplasia ossificans progressive (FOP), announced that Health Canada approved oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema attacks in patients 12 years and older.

In April 2022- Takeda Pharmaceutical Company Limited, a research-based global company, announced that TAKHZYRO injection single-dose prefilled syringes were available in the U.S. to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years and older.

The increasing number of hereditary angioedema (HAE) cases and its genetic nature are expected to drive the market growth during the forecast period. HAE, an inherited disorder, means that individuals with the condition may pass on the defective gene to their offspring, leading to a higher disease prevalence. This continuous transmission of the faulty gene across generations creates a sustained demand for effective treatments and therapies, stimulating the development and adoption of innovative solutions in the angioedema treatment market. As awareness about HAE and genetic testing improves, early diagnosis and intervention might become more prevalent, further driving the need for advancements in medical interventions, thereby propelling market growth. According to a May 2022 article by the National Center for Biotechnology Information, the global estimated prevalence of hereditary angioedema is 1 in 50,000 individuals. Moreover, the NORD (National Organization for Rare Disorders) states that the risk of passing the abnormal gene from an affected parent to their offspring is 50% for each pregnancy, irrespective of the child's gender. These statistics highlight the substantial impact of hereditary nature on the disease's prevalence and underline the potential driving force behind the growth of the angioedema treatment market. Furthermore, misdiagnosing angioedema as common allergy, appendicitis, or irritable bowel syndrome has significantly hindered effective treatment and adversely affected the growth of the angioedema treatment market. Due to its overlapping symptoms with other conditions, many HAE cases remain undiagnosed or are misdiagnosed, leading to delayed or inappropriate treatment. This diagnostic challenge may result in prolonged suffering for patients, worsening of symptoms, and increased healthcare costs. Additionally, healthcare professionals may not be adequately informed about HAE, leading to missed opportunities for timely intervention and the initiation of appropriate therapies. This lack of accurate and early diagnosis impedes the demand for specific angioedema treatments and limits the potential market growth.

Angioedema Treatment Market Segmentation:

By Condition Type

Allergic angioedema
Drug-induced angioedema
Idiopathic angioedema
Hereditary angioedema (HAE)

By Drug Type

C1 esterase inhibitor
- Cinryze
- Berinert
- Ruconest
- Haegarda
Selective bradykinin B2 receptor antagonist
- Firazyr
Kallikrein inhibitor
- Kalbitor
Others

By Route of Administration

Injection
- Intravenous
- Subcutaneous
Oral

By Distribution Channel

Hospitals
Retail pharmacies
Online pharmacies

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the growing incidence of hereditary angioedema, the presence of key players, rising awareness programs and research organizations regarding the treatment of the condition and established healthcare infrastructure. The increasing government initiatives, growing research partnerships, and a robust pipeline are the major growth drivers of the market. For instance, In September 2021, Cycle Pharmaceuticals launched SAJAZIR injection, a new treatment option for patients affected by hereditary angioedema (HAE) approved by the US FDA. The region has many government- and non-government-funded research institutions. Therefore, above mentioned factors are likely to register significant growth during the forecast period.

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Angioedema Treatment Market By Condition Type, By Drug Type, By Route of Administration, By Distribution Channel and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Angioedema Treatment Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Angioedema Treatment Market Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Angioedema Treatment Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Angioedema Treatment Market, By Condition Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Allergic angioedema
  2. Drug-induced angioedema
  3. Idiopathic angioedema
  4. Hereditary angioedema (HAE)
8. Angioedema Treatment Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. C1 esterase inhibitor
  1.1. Cinryze
  1.2. Berinert
  1.3. Ruconest
  1.4. Haegarda
  2. Selective bradykinin B2 receptor antagonist
  2.1. Firazyr
  3. Kallikrein inhibitor
  3.1. Kalbitor
  4. Others
9. Angioedema Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Injection
  1.1. Intravenous
  1.2. Subcutaneous
  2. Oral
10. Angioedema Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Hospitals
  2. Retail pharmacies
  3. Online pharmacies
11. North America Angioedema Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
12. Latin America Angioedema Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
13. Europe Angioedema Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
14. Asia Pacific Angioedema Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
15. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Saudi Arabia
  2.2. UAE
  2.3. South Africa
  2.4. Egypt
  3. Market Size (USD Million) Forecast for MEA 2023-2031
16. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Shire plc.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. CSL Limited
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Pharming Group NV
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Ionis Pharmaceuticals, Inc.
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. iBio Inc.
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. BioCryst Pharmaceuticals, Inc.
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
18. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients